PMID- 24008338
OWN - NLM
STAT- MEDLINE
DCOM- 20140801
LR  - 20151119
IS  - 1421-9867 (Electronic)
IS  - 0012-2823 (Linking)
VI  - 88
IP  - 3
DP  - 2013
TI  - Sleep disturbances and refractory gastroesophageal reflux disease symptoms in 
      patients receiving once-daily proton pump inhibitors and efficacy of twice-daily 
      rabeprazole treatment.
PG  - 145-52
LID - 10.1159/000354071 [doi]
AB  - BACKGROUND: Nighttime acid reflux that influences refractory symptoms is strongly 
      associated with sleep disturbances. The aim of this study was to examine the 
      associations between sleep disturbances and refractory gastroesophageal reflux 
      disease (GERD) symptoms in patients receiving once daily proton pump inhibitors 
      (PPI) and the efficacy of twice-daily rabeprazole treatment. METHOD: In a 
      multicenter survey, 433 GERD patients receiving once-daily PPI treatment 
      completed a self-report questionnaire that included the Frequency Scale for the 
      Symptoms of GERD (FSSG) and questions about sleep disturbances. Study cases were 
      defined as patients with an FSSG score >/=8. Of the 222 study cases, 106 
      individuals received rabeprazole 10 mg twice daily for 4-8 weeks. RESULTS: Of the 
      433 subjects, 222 patients revealed FSSG scores of >/=8. Use of a half dose of PPI 
      was associated with such cases. PPI-refractory symptoms were found in 46% of 
      patients with standard-dose PPI treatment. Nighttime symptoms (OR = 2.56), 
      daytime sleepiness (OR = 1.64), and poorer sleep quality (OR = 1.67) were 
      significantly associated with refractory GERD symptoms. Twice-daily rabeprazole 
      treatment significantly improved FSSG scores and sleep disturbances. CONCLUSION: 
      About half of the GERD patients receiving once-daily standard-dose PPI treatment 
      had refractory GERD symptoms. Sleep disturbances were significantly associated 
      with refractory GERD symptoms. Twice-daily rabeprazole treatment was effective in 
      such cases.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
FAU - Fujiwara, Yasuhiro
AU  - Fujiwara Y
AD  - Department of Gastroenterology, Osaka City University Graduate School of 
      Medicine, Osaka, Japan.
FAU - Habu, Yasuki
AU  - Habu Y
FAU - Ashida, Kiyoshi
AU  - Ashida K
FAU - Kusano, Motoyasu
AU  - Kusano M
FAU - Higuchi, Kazuhide
AU  - Higuchi K
FAU - Arakawa, Tetsuo
AU  - Arakawa T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20130905
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (Proton Pump Inhibitors)
RN  - 32828355LL (Rabeprazole)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Gastroesophageal Reflux/complications/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*administration & dosage
MH  - Rabeprazole/*administration & dosage
MH  - Sleep Wake Disorders/*etiology
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2013/09/07 06:00
MHDA- 2014/08/02 06:00
CRDT- 2013/09/07 06:00
PHST- 2013/04/12 00:00 [received]
PHST- 2013/06/19 00:00 [accepted]
PHST- 2013/09/07 06:00 [entrez]
PHST- 2013/09/07 06:00 [pubmed]
PHST- 2014/08/02 06:00 [medline]
AID - 000354071 [pii]
AID - 10.1159/000354071 [doi]
PST - ppublish
SO  - Digestion. 2013;88(3):145-52. doi: 10.1159/000354071. Epub 2013 Sep 5.